A small amount of the virus detected in humans can be sprayed into the nostrils to prevent COVID-19 infection before it appears and to be treated early if given immediately after infection, according to a study in rats led by Cornell University researchers.
The study, published in Nature, used experimental rats used in conjunction with human receptors for coronavirus on top of the cell and detected the virus, named N-0385, by inhibiting the entry of the virus into cells in the body. At Cornell, N-0385 was shown to protect rats from infection before exposing, while also giving effective treatment when administered up to 12 hours after exposure. This cell was developed in collaboration with researchers at Sherbrooke University in Quebec, Canada.
The drug promises both prevention and reduction of severity and mortality from COVID-19 after infection with a single dose of regular doses.
“There are very few, if any, microorganisms that have been identified that work by immunity to prevent infection,” said Hector Aguilar-Carreno, assistant professor of pathology, and senior editor of the newspaper.
“This is the first of its kind,” said Aguilar-Carreno. “Another benefit is that it works early in infection, even after someone has already been infected.”
The main spectrum was tested in rats exposed to the first species detected in the United States in Washington state in 2020, as well as the Delta species, but it was not tested on the Omicron variant, although they the research have high hopes it will be effective. .
Researchers have introduced small particles in the nose in rats before, during, and / or after infection.
They tracked the weight of the mice-like weight loss Infection signal is also a good indicator of disease- and other clinical and pathological parameters, such as temperature and mortality, and mouse analysis to understand how mice respond well. The solution is to stop beraye from weight loss, before the appearance of the coronavirus, and from death after infection. Even up to 12 hours after infection, treatment shows very good results, says Aguilar-Carreno.
A California company, EBVIA Therapeutics, Inc., is currently raising funds for tempting people, drug developmentplanning and production rate. If funds are raised quickly, and if a human test proves successful, the hope is that the drug can be submitted for FDA emergency approval within a minimum of six months.
“The N-0385 solution is simpler and less expensive for mass production than other forms of COVID-19 treatment, such as monoclonal antiviral drugs,” said Aguilar-Carreno.
Tirosh Shapira et al, A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic, Nature (2022). DOI: 10.1038 / s41586-022-04661-w
hint: Promising nasal spray can prevent, treat COVID-19 (2022, March 28) restored 28 March 2022 from https://medicalxpress.com/news/2022-03-nose-covid-.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Promising nose spray could prevent, treat COVID-19 Source link Promising nose spray could prevent, treat COVID-19